Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Antiviral deal coming?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1345)
•••
Comment by CancerSlayeron Oct 08, 2024 9:14pm
222 Views
Post# 36258746

RE:RE:Antiviral deal coming?

RE:RE:Antiviral deal coming?
Donein25 wrote: Did anyone see the J&J news today; they dropped a Phase 3 bladder cancer (muscle invasive) trial. The same drug was already successfully tested in NMIBC with 82% CR. They value their potential market share at $5B. 



I'm not too surprised that J&J halted their MIBC Ph 3 study of the Tar-200, which is a catheter-inserted intravesical device.  The Tar-200 is used to deliver chemo (i.e. Gemcitabine in NMIBC) within the bladder.  Intravesical therapies are generally more effective for superficial cancers like NMIBC, but likley inappropriate for deeper-seated cancers like MIBC.

The Tar-200 device allows for a controlled/sustained release of chemo over many days/weeks, likely allowing for improved tumor absorption of a drug.  Per the PI of the J&J NMIBC study, this type of device could presumably be used with other drugs, which makes this device tech an exciting opportunity to be potentially utilized with our compound(s) & others.

It is possible that the primary success-limiting factor of our ACT may not necessarily be due to our unique drug MoA or activation source, but rather the allotted time for drug absorption &/or light-energy delivery.  JMO.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities